GlassScriptPhysician profile
Amanda B Davis
NPI 1790220143
$46,484.76
in general payments reported to CMS, 2019-2025
17 companies · $5,191 in 2025
The $5,191 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $3,905 · 2023: $18K · 2024: $19K · 2025: $5,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $12K · Consulting Fee: $5,720 · Food and Beverage: $2,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,160.00 |
| Travel and Lodging | $11,718.94 |
| Consulting Fee | $5,720.00 |
| Food and Beverage | $2,837.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41,612.21 | 2022-2025 | Epclusa |
| Abbvie INC. | $3,812.15 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.44 | 2022-2024 | Xifaxan, Plenvu |
| Ipsen Biopharmaceuticals, INC | $245.41 | 2024-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $75.87 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $58.45 | 2025 | Rezdiffra |
| Medtronic, INC. | $35.14 | 2023 | Interstim |
| Sunovion Pharmaceuticals INC. | $28.23 | 2021 | |
| Merck Sharp & Dohme LLC | $27.03 | 2021-2022 | |
| Janssen Biotech, INC. | $24.81 | 2025 | Tremfya |
| Orphalan INC | $19.12 | 2025 | Cuvrior |
| Phathom Pharmaceuticals, INC. | $19.08 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $18.80 | 2021 | |
| Novo Nordisk INC | $18.12 | 2025 | Wegovy |
| Ardelyx, INC. | $16.85 | 2025 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $14.14 | 2024 | Talicia |
| Currax Pharmaceuticals LLC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.